--- title: "TRETHERA CORP — Capability Statement" uei: "QB66ZMAUF5P7" cage: "7NJ74" canonical: "https://teamingindex.com/contractor/QB66ZMAUF5P7/capability.md" html_url: "https://teamingindex.com/contractor/QB66ZMAUF5P7" updated: "2026-11-09T17:28:18.052Z" generator: "TeamingIndex capability twin 1.0" legal_name: "TRETHERA CORP" primary_naics: "541714" sam_status: "active" active_exclusion: false claimed: false tier: "unclaimed" --- # TRETHERA CORP > TRETHERA CORP is a SAM.gov-registered entity based in SHERMAN OAKS, CA 91423-4807. UEI QB66ZMAUF5P7; CAGE 7NJ74; primary NAICS 541714. Compliance posture not provided. Active SAM registration. > **Unclaimed profile:** seeded from SAM.gov and USAspending public records. The entity has not claimed it, so capabilities and compliance posture have not been provided. ## Identifiers - **Legal business name:** TRETHERA CORP - **UEI (SAM.gov Unique Entity ID):** QB66ZMAUF5P7 - **CAGE code:** 7NJ74 - **Entity structure:** Corporate Entity (Not Tax Exempt) - **State of incorporation:** DE - **Website:** - **TeamingIndex profile:** - **Profile status:** Unclaimed · seeded from SAM.gov and USAspending public records ## Location - **Physical address (city, state, ZIP):** SHERMAN OAKS, CA 91423-4807 - **Country:** United States - **Congressional district:** CA-32 ## NAICS & PSC | NAICS | Title | Primary | Small under SBA size standard (SAM.gov) | | --- | --- | --- | --- | | 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | Yes | Yes | | PSC | Name | | --- | --- | | 6505 | DRUGS AND BIOLOGICALS | - **PSC names:** Acquisition.gov PSC Manual (April 2025 edition) Size status is NAICS-specific and reflects the entity’s SAM.gov representations; check it against the size standard of the solicitation’s NAICS code. ## Socio-economic status - Small Business (SB) Source: SAM.gov entity registration, synced 2026-11-09. Confirm current SBA certification (8(a), HUBZone, WOSB/EDWOSB, VetCert SDVOSB/VOSB) before relying on a status for a set-aside. ## SAM registration & exclusion screening - **Registration:** Active SAM registration - **Registration expires:** 2027-04-16 - **Registration activated:** 2026-04-20 - **Exclusion screening (FAR subpart 9.4):** No active exclusion recorded in SAM.gov - **Teaming eligibility:** Eligible to be proposed as a team member (active registration, no exclusion) - **Source:** SAM.gov Entity Management, synced 2026-11-09 ## Compliance posture Compliance posture not provided by the contractor. - Facility clearance: visible to paid members - Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). ## Contract vehicles No contract vehicle holdings on file. ## Past performance - **Total obligated, trailing 36 months (USAspending.gov):** $0 - **Award history:** 0 awards on record No federal prime awards on record (USAspending.gov). ## Proven teaming graph - No first-tier sub-award reports name this company yet - Source: USAspending.gov sub-award reports (FSRS), sync date not recorded. Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values. ## SBIR/STTR portfolio - SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects - 11 SBIR/STTR awards totaling $10.8M: SBIR Phase II 4, STTR Phase I 4, STTR Phase II 2, SBIR Phase I 1 - By agency: Department of Health and Human Services 11 - Active projects (contract end date ahead): 3 - Phase II awards ending within 12 months: 2 - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2025, Sep 8, 2025 to Aug 31, 2026: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer ($406,500) - STTR Phase II, Department of Health and Human Services (National Institutes of Health), 2025, Sep 3, 2025 to Aug 31, 2027: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease ($905,290) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2025, Aug 18, 2025 to Jul 31, 2027: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors ($1,150,000) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2025, Aug 7, 2025 to Jul 31, 2028: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus ($994,978) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2024, Jul 2, 2024 to Jun 30, 2026: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) ($2,050,000) - STTR Phase II, Department of Health and Human Services (National Institutes of Health), 2024, Feb 1, 2024 to Jan 31, 2026: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis ($1,238,306) - STTR Phase I, Department of Health and Human Services (National Institutes of Health), 2023, Sep 18, 2023 to Aug 31, 2024: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease ($395,119) - STTR Phase I, Department of Health and Human Services (National Institutes of Health), 2023, Aug 1, 2023 to Jul 31, 2025: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) ($601,607) - STTR Phase I, Department of Health and Human Services (National Institutes of Health), 2023, Jun 21, 2023 to May 31, 2025: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus ($610,850) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2023, Jun 1, 2023 to May 31, 2025: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types ($2,046,375) - Phase III: Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual. - Source: SBIR.gov award data file, as of Nov 12, 2026 (file published Nov 1, 2026) ## FedRAMP offerings - No FedRAMP Marketplace listing is linked to this company - Source: FedRAMP Marketplace, sync date not recorded ## Exclusions & screening - Not yet checked against SAM.gov exclusions (search exclusions on SAM.gov: https://sam.gov/search/?index=ex) - Source: SAM.gov Exclusions, sync date not recorded - No confirmed match on the Consolidated Screening List (screened Nov 13, 2026) ## Contract vehicles on federal record - No contract-vehicle seats on federal record are linked to this company ## GSA CALC+ rates - No GSA CALC+ awarded ceiling rates on record for this company - Source: GSA CALC+ awarded ceiling rates, sync date not recorded. Ceiling rates are the most an agency can be charged, not prices paid ## Capabilities & differentiators No capability narrative published. ## Technical tags No technical tags published. ## Teaming preferences - Teaming preferences not published - **Teaming requests and NDAs:** request an introduction on the TeamingIndex profile (sign-in required): ## Business development contact No business-development contact published. ## Corporate hierarchy - No parent entity reported in SAM.gov - Affiliation with a parent or sister concerns can affect small-business size status (13 CFR 121.103). ## Provenance & disclaimer - **SAM.gov entity registration** (identifiers, NAICS/PSC, size and socio-economic status, hierarchy, registration and exclusion status): synced 2026-11-09 - **USAspending.gov** (prime award history and trailing 36-month obligations): nightly sync - **Contractor-provided profile** (capabilities, teaming preferences, self-attested compliance): not provided - **TeamingIndex verification** (credentials marked “Verified by TeamingIndex”): no verified credentials on record; methodology: - **Blind SPRS:** exact NIST SP 800-171 SPRS scores are published only when the contractor opts in; brackets are cumulative thresholds (SPRS ≥ 0, SPRS ≥ 50, SPRS ≥ 70, SPRS ≥ 85, SPRS ≥ 95, SPRS ≥ 105, SPRS = 110 (perfect)). - **Before award:** self-attested facts have not been independently verified. Confirm registration and exclusions in SAM.gov, CMMC status and SPRS assessment currency with the contractor (DFARS 252.204-7019, -7020 and -7021), facility clearances through DCSA’s NISS, AS9100-series certificates in the IAQG OASIS database, and FedRAMP authorizations on the FedRAMP Marketplace. - **Zero CUI:** this document contains no Controlled Unclassified Information. TeamingIndex stores verification metadata only, never SSPs, POA&Ms or DD Form 254s. - **Machine-readable:** schema.org JSON-LD is embedded in ; this twin: ; site index: © 2026 HILARTECH, LLC. All rights reserved. TeamingIndex.com is an independent defense industrial base intelligence platform owned and operated by HILARTECH, LLC and is not affiliated with or endorsed by the U.S. Department of Defense (DoD), the General Services Administration (GSA), or SAM.gov.